Ansell Limited

The Business

Ansell manufactures personal protective equipment across two divisions: Healthcare, supplying surgical and examination gloves plus cleanroom protection to hospitals and life sciences customers, and Industrial, providing cut-resistant, chemical and mechanical protective gloves to manufacturing and construction customers. Its top five brands, including HyFlex, GAMMEX and Kimtech, generate 58% of group sales and carry regulatory-driven switching costs that are hard for hospitals and cleanrooms to bypass quickly. The 2024 acquisition of Kimberly-Clark's PPE business added a cleanroom franchise now growing well ahead of the group average, pushing Ansell into genuine niche leadership.

Recent Performance

FY26 revenue grew 6.8% to $2,140m, decelerating from FY25's 23.7% jump, a comparison that flatters FY25 given the partial-year consolidation of the newly acquired PPE business that year. EBIT margin expanded to 15.0% from 14.1%, driven by $50m of realised cost savings and favourable cleanroom mix. The share price has re-rated on the back of that margin story and now trades near record highs.

Outlook

We expect revenue growth to decelerate gradually over the next few years as cleanroom growth normalises from its current double-digit pace toward high single digits, with EBIT margin easing modestly from current levels as gross margin gives back some of its recent gains. Margin trajectory is the single biggest driver of returns from here, more consequential than revenue growth or any other input. Earnings per share growth is expected to slow well below FY26's step-change pace, because operating leverage has largely disappeared now that margins sit near their ceiling.

Key Risks

Margin mean reversion is the largest single risk facing the thesis. EBIT margin at 15.0% sits close to its all-time peak, and a reversion toward the historical average would meaningfully compress earnings, likely triggered by renewed price competition from Asian glove manufacturers rebuilding capacity or a fading of the cleanroom mix benefit. Currency exposure compounds this: because Ansell reports in US dollars but trades in Australian dollars, a rise in the AUD would erode fair value with no change whatsoever to the underlying business, a structural mismatch that cannot be hedged away at the shareholder level. Elevated Middle East-driven input costs pose a further risk if pricing increases continue to lag cost inflation, though management has so far fully offset these costs through pricing without evident volume loss.

What to Watch

The thesis-defining event is the half-year result in February 2027, which will confirm whether EBIT margin can hold near current levels or begins to compress as our model assumes.

• 6-18 months Middle East resolution lowering input costs — would ease NBR latex and energy cost pressure.
• 12-24 months Cleanroom growth sustaining above 10% — continued pharma and semiconductor reshoring demand would support the growth segment beyond current base-case assumptions.

Company Description

Ansell operates two divisions: Healthcare, roughly 56% of revenue, supplying surgical and examination gloves plus cleanroom protection to hospitals and life sciences customers, and Industrial, roughly 44% of revenue, providing cut-resistant, chemical and mechanical protective gloves to manufacturing, construction and automotive customers. The 2024 acquisition of Kimberly-Clark's PPE business added a life sciences cleanroom franchise, integrated alongside $50m of annual cost synergies now fully realised. Manufacturing spans 14 plants across 8 countries, a footprint built for tariff and supply chain flexibility rather than lowest-cost concentration alone.

Where the Growth Is

Cleanroom and life sciences protection, inherited through the 2024 acquisition, is Ansell's most important growth engine. The segment holds a 20-25% share in a niche protecting pharmaceutical and semiconductor manufacturing environments, growing 10-17% annually versus a 4-5% group average, driven by tightening GMP regulatory standards and reshoring of chip manufacturing. If this growth rate holds above 10% over the next one to two years, it represents upside that sits beyond current base-case assumptions, which already price in some deceleration as the segment matures.

Competitive Position

Ansell's top five brands generate 58% of group sales and carry regulatory-driven switching costs: hospitals and cleanrooms must revalidate supply chains before changing glove suppliers, a process that can take 12-24 months. This creates a durable but not unassailable advantage, one we expect to persist for five to seven years rather than indefinitely. The advantage sits in specialised categories, surgical synthetics, cleanroom, cut-resistant industrial, not in commodity examination gloves, where Asian manufacturers such as Top Glove and Hartalega compete on price and are rebuilding capacity after pandemic-era overbuilding. The multi-region manufacturing footprint let Ansell price around both Middle East-driven input cost inflation and new US tariffs in FY26 without apparent volume loss. Return on invested capital of 12.7% comfortably exceeds its cost of capital, though the spread has been narrowing.

Management & Capital Discipline

Over the past three to five years, management has funded organic capital expenditure, a 45% dividend payout ratio, an active buyback program and continued deleveraging, all while integrating the recent acquisition and delivering its promised $50m in annual cost savings on schedule. That execution record is genuinely strong. The honest gap is at the top: the new chief executive, in the role less than a year, has so far articulated only generic strategic themes, "customer centricity" and "simplification", without a clear statement of what drives earnings once the current cost and mix tailwinds are exhausted.

Financial Position

Ansell's balance sheet is a genuine strength, carrying moderate leverage, an investment-grade credit profile, and strong free cash flow conversion in FY26. This capacity supports the dividend, ongoing buybacks and bolt-on acquisitions without straining the balance sheet, and gives the company room to absorb a period of margin softness or a cyclical downturn without threatening its capital return program.